{
  "docId": "019de074-4969-72b8-bf99-262b9202adeb",
  "docSlug": "32d16c961ba3228c7796678a3b67d91c",
  "documentTitle": "ATAI | Investor Presentation Deck | 33 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 33,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 84,
  "notes": "The slide uses a numbered list to highlight key safety findings alongside a detailed data table.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-4969-72b8-bf99-262b9202adeb/23",
  "deckHref": "/decks/019de074-4969-72b8-bf99-262b9202adeb",
  "deckJsonHref": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json",
  "deckAnchorHref": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.25,
        "x": 0.73,
        "y": 0.92
      },
      "kind": "callout",
      "text": "Preliminary data, subject to change",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe6e726d-6714-48eb-8508-db20ea26d516",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.35,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "list",
      "text": "1. Given every 12 hours for 7 days, GRX-917 was well-tolerated with no dose-limiting toxicities identified up to the highest dose of 300mg\n2. There were no serious adverse events reported nor dose-related discontinuations due to adverse events\n3. Adverse events in both single- and multiple-ascending dose (SAD and MAD) regimens were comparable to placebo-treated subjects\n4. No significant evidence of sedation or other benzodiazepine-like side effects at any doses tested",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4a5a01f4-c81a-4144-b62b-05a4b973e124",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.05,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Note: TEAE = Treatment-emergent Adverse Event, SAD = Single Ascending Dose, MAD = Multiple Ascending Dose. 1. n = number of subjects reporting at least one TEAE in that category, % = proportion of cohort total. 2. Defined as an adverse event that began after the start of trial medication treatment. 3. Non-exhaustive. Other recorded TEAEs included Upper respiratory tract infection (3%), Rash erythematous (3%), Dysmenorrhoea (3%), Catheter site pain (3%). 4. Of the 565 patients given XANAX in Ph.3 placebo-controlled trials for anxiety disorders, 41% reported drowsiness versus 22% of those administered placebo (as reported in XANAX FDA label)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d5ffb505-c06e-43d6-8850-c6d89f98acd2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.55,
        "x": 0.42,
        "y": 0.23
      },
      "kind": "table",
      "text": "GRX-917 Phase 1 MAD study safety data table showing TEAEs by dose group",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dfda47c2-3080-4e88-8a0b-5f5524121e77",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "GRX-917 Phase 1 data: No severe or serious adverse events, with minimal sedation or dizziness, confirms favourable safety profile",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4eecca1e-c02f-44ae-b001-19902a981163",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 33,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae",
      "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.",
      "position": 1,
      "objective": "Why is atai Life Sciences' solution important?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}